Synapse - Works

Results (115370)

Impact of type of hypomethylating agent (HMA) used on outcomes of patients (pts) with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) - A large, multicenter, retrospective analysis

Meeting Abstract

Bewersdorf, J. P.; Kewan, T.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; more...
Blood (2023)

Fulltext@MSK | Save

First results from a phase 1, first-in-human study of the Bruton's tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) B-cell malignancies (BGB-16673-101)

Meeting Abstract

Seymour, J. F.; Cheah, C. Y.; Parrondo, R.; Thompson, M. C.; Stevens, D. A.; Lasica, M.; Wang, M. L.; Kumar, A.; Trotman, J.; Alwan, M.; more...
Blood (2023)

Fulltext@MSK | Save

Dexamethasone is associated with a lower incidence and severity of cytokine release syndrome compared with other corticosteroid regimens when given as premedication for glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)

Meeting Abstract

Falchi, L.; Carlo-Stella, C.; Morschhauser, F.; Dickinson, M.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez-Lopez, J.; Bartlett, N. L.; more...
Blood (2023)

Fulltext@MSK | Save

Long-term results from the OPTIC trial: A dose-optimization study of 3 starting doses of ponatinib

Meeting Abstract

Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Undurraga, S.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
Blood (2023)

Fulltext@MSK | Save

Outcomes in patients with classical Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: Real world analysis from 14 US academic centers

Meeting Abstract

Voorhees, T.; McLaughlin, E.; Torka, P.; Florindez, J. A.; Moyo, T. K.; Reves, H.; Sumransub, N.; Deshpande, S.; Rose, A.; Duarte, C.; more...
Blood (2023)

Fulltext@MSK | Save

Updated safety and efficacy results of ABBV-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed/refractory multiple myeloma

Meeting Abstract

Vij, R.; Kumar, S. K.; D'Souza, A.; McKay, J. T.; Voorhees, P. M.; Chung, A.; Tuchman, S. A.; Korde, N.; Weisel, K.; Teipel, R.; more...
Blood (2023)

Fulltext@MSK | Save

A phase 1 study of PIT565, a first-in-class, anti-CD3, anti-CD19, anti-CD2 trispecific antibody in patients with relapsed and/or refractory B-cell malignancies

Meeting Abstract

Mazza, I. A.; Barba, P.; Yuda, J.; Palomba, M. L.; Alderuccio, J. P.; De Vriendt, C.; Corradini, P.; Lim, F. L. W. I.; Zinzani, P. L.; Jain, N.; more...
Blood (2023)

Fulltext@MSK | Save

Influence of pre-treatment features and therapy choice by physicians on overall survival in older adults with acute myeloid leukemia: A report from the beat AML master trial

Meeting Abstract

Borate, U. M.; Huang, Y.; Welkie, R. L.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; more...
Blood (2023)

Fulltext@MSK | Save

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in patients (pts) with myelodysplastic syndromes/neoplasms (MDS) who underwent allogenic stem cell transplantation (HSCT)

Meeting Abstract

Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; more...
Blood (2023)

Fulltext@MSK | Save

Genomic characterization of newly diagnosed acute myeloid leukemia in patients age 60 years and older; A report from the beat AML master trial

Meeting Abstract

Hoff, F. W.; Huang, Y.; Welkie, R. L.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Patel, P. A.; Collins, R. H.; Baer, M. R.; more...
Blood (2023)

Fulltext@MSK | Save